Home Combat Arthritis Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Jan 27, 2021 comments off

Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Investors are excited about the biotech’s clinical trial results.

Read More…

You May Also Like

U.S. FDA seeks new warnings on drugs from Pfizer, Lilly and AbbVie – Reuters

Antibody levels higher after Moderna shot; Lilly arthritis drug used with steroid cuts death risk – Reuters

WHO-led trial to study three anti-inflammatory drugs for COVID-19 patients – Reuters India

Podiatrists debunk 12 feet myths

NIH starts study of COVID-19 booster shot in people with autoimmune diseases – Reuters

Pharma Stock Roundup: PFE's COVID Jab Full Approval by FDA, JNJ's Booster Data